Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Heart failure (HF) is a growing global public health burden. However, due to the very limited regenerative capacity of mature cardiomyocytes in the adult mammalian heart, conventional treatments can only improve the symptoms of HF but fail to restore cardiac function. Heart transplantation is limited by a severe shortage of donors. Cell-based transplantation for the treatment of HF has become a promising strategy. Human-induced-pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been tested in animal models to assess safety and efficacy. This study aims at evaluating the safety and efficacy of epicardial injection of hiPSC-CMs in patients with advanced HF during coronary artery bypass grafting (CABG) surgery. METHODS: cells, sequentially). Patients with advanced heart failure will be enrolled and randomly allocated to receive epicardial injection of hiPSC-CMs during CABG surgery or CABG surgery alone, followed by a 12-month follow-up investigation. The primary endpoint is to assess the safety of hiPSC-CMs transplantation, including haemodynamic compromised sustained ventricular arrhythmias and newly formed tumours during 6 months postoperatively. The secondary endpoint is to evaluate the efficacy of epicardial injection of hiPSC-CMs and CABG surgery combination by comparison with CABG surgery alone. ETHICS AND DISSEMINATION: The study protocol has been approved by the Institutional Ethical Committee of Nanjing Drum Tower Hospital (No. SC202000102) and approved by National Health Commission of the PRC (MR-32-21-014649). Findings will be disseminated to the academic community through peer-reviewed publications and presentation at national and international meetings. TRIAL REGISTRATION NUMBER: NCT03763136.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another group in China, at Help Therapeutics, proposed using iPSC-derived cardiomyocytes to treat ischemic heart failures [78].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
Epidemiology and aetiology of heart failure
Ziaeian, B., & Fonarow, G. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.25 · Cited by 1,878
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Myocardial Interstitial Fibrosis in Heart Failure
González, A., Schelbert, E. B., Díez, J., & Butler, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.021 · Cited by 660
Liu, Y.-W., Chen, B., Yang, X., Fugate, J. A., Kalucki, F. A., Futakuchi-Tsuchida, A., Couture, L., Vogel, K. W., Astley, C. A., Baldessari, A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4162 · Cited by 617
Kawamura, M., Miyagawa, S., Miki, K., Saito, A., Fukushima, S., Higuchi, T., Kawamura, T., Kuratani, T., Daimon, T., Shimizu, T., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.084343 · Cited by 495
Menasché, P., Vanneaux, V., Hagège, A., Bel, A., Cholley, B., Parouchev, A., Cacciapuoti, I., Al-Daccak, R., Benhamouda, N., Blons, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.047 · Cited by 456
Cited by
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2024.12.005 · Cited by 196
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials
Zhang, J. J., Pogwizd, S. M., Fukuda, K., Zimmermann, W., Fan, C., Hare, J. M., Bolli, R., & Menasché, P. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01098-8 · Cited by 58
Csöbönyeiová, M., Beerová, N., Klein, M., Čeháková, M., & Danišovič, Ľ. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810314 · Cited by 42
Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells
Sugiura, T., Shahannaz, D. C., & Ferrell, B. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115772 · Cited by 35
Metadata
- Authors
- Zhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., Zhou, Q., Yang, G., Wang, J., & Wang, D.-J.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Nanjing Drum Tower Hospital (CN)
- Department of Cardiothoracic Surgery, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- HELP Therapeutics (China) (CN)
- Corresponding author
- Wang, Jiaxian
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2022-05
- Volume
- 12
- Issue
- 5
- Pages
- e056264
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC9083430
- OpenAlex
- W4229069980
- Cited by
- 44
- References
- 27
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 11 · 2023: 9 · 2022: 3
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- Funders
- Help Therapeutics (NA)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- advanced heart failure, human induced pluripotent stem cell-derived cardiomyocytes, coronary artery bypass grafting, allogeneic cell transplantation, cell transplantation safety, ventricular arrhythmias, tumor formation
- MeSH terms
- Coronary Artery Bypass, Heart Failure, Humans, Randomized Controlled Trials as Topic, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Hematopoietic Stem Cell Transplantation, Myocytes, Cardiac, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. https://app.cochat.ai/papers/10.1136/bmjopen-2021-056264
- The paper
- Zhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., Zhou, Q., Yang, G., Wang, J., & Wang, D.-J. (2022). Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open. https://doi.org/10.1136/bmjopen-2021-056264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
